"Today Fisher entered into a definitive agreement to acquire privately held Cellomics, Inc. for approximately $49 million in cash. Cellomics, with 2004 revenues of approximately $13 million, is a worldwide leader in the high-content-screening segment of the cellular-analysis market. The addition of Cellomics will build on Fisher's offering of drug-discovery solutions in the life-science marketplace, enabling researchers to accelerate the process of developing new medicines. In connection with this acquisition, Fisher and Carl Zeiss Jena GmbH, Cellomics' largest shareholder, agreed to closely collaborate in the high-content-screening field going forward."
genomeweb.com
I had a vague notion that stuff like this
(or Tissueinformatics, if it is worth anything)
would be useful to an outfit like GLGC--with
their large bank of tissue samples and such...
I mentioned it on one of the yahoo threads, and
the idea was immediately dismissed 'tissueinfomatics
has been written down' that is, the value has been
written off the books. I am no accountant, but
simply writing something off doesn't make it
truly worthless in my mind. I know I am stating
the obvious...repeatedly.
burrillandco.com
Also from the Burrill website
"The uniqueness of Icoria’s proprietary systems biology platform is a direct benefit of its leadership role in metabolomics and its ability to digitally measure tissue phenotypes, which was made possible through the acquisition of TissueInformatics.Inc"
It may very well be that there is no value in Icoria,
or Tissueinformatics. In that case, you were snookered
at $5 4 3 2 1....but at least I did not overpay, and
if icoria goes from a marketcap of $7m to zero, so be it. |
